Inhibitors of CACNA1A/ALPHA1A subunit internal ribosomal entry site (IRES) and methods of treating spinocerebellar ataxia type 6
US10017765B2 · kind B2 · utility
1Cited by
1References
13Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jul 2, 2014 |
| Grant date | Jul 10, 2018 |
| Priority date | — |
| Expiry date | Jul 2, 2034 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12N2320/30
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The disclosure provides methods of treating polyglutamine diseases, e.g., spinocerebellar ataxia Type 6, in a subject, comprising administering to the subject an IRES inhibitor in an amount effective for treating the SCA6 in the subject. Also provided herein are the IRES inhibitors, and pharmaceutical compositions comprising the same.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.